跳至主內容 Skip to main content
Fund Profile · Fund Details

Manulife MPF Healthcare Fund

Manulife Global Select (MPF) Scheme

Manulife Risk class 5
—
1-YR RETURN · P.A.
+5.36%
5-YR RETURN · P.A.
1.91298%
FUND EXPENSE RATIO
eMPF fee cut: completed
5/7
RISK CLASS
53,239.0m
FUND SIZE

Data as of 2026-06-30

Fund Commentator

Straight talk on this fund

  • Risk class 5, near the top of the scale. Worst calendar year on record: 2016 (-3.2%). That kind of drawdown separates the patient from the panicked.
  • Top 10 holdings (Merck & Co., Inc, Novartis AG ADRJohnson & Johnson, Eli Lilly and Co.…) are 52.5% of the fund — over half the fund in ten names. The manager is betting big on a few stocks rather than owning the whole market. The top three (Merck & Co., Inc, Novartis AG ADRJohnson & Johnson, Eli Lilly and Co.) alone are 21.7%: when those names move, the fund moves with them.
  • The objective promises a diversified portfolio, but 52.5% sits in the top 10 — that's concentration, not diversification. The label and the portfolio are telling different stories.
  • In its best calendar year (2019) it made 9.4%; in its worst (2016) it lost 3.2% — that range tells you what you're signing up for.
  • For monthly contributors, volatility can be a friend (buy more when down). Near retirement, that ride needs a second thought. When markets are choppy, position size itself is a decision.
◎

Manager's LensWhat the portfolio reveals about the manager's thinking

Allocation

Top-10 holdings are 52.5% of the fund. Merck & ., at 7.3% is the largest single position. The top three together are 21.7%. This is a concentrated portfolio. High conviction — or high concentration risk, depending on your view. Within the top 10, by sector: healthcare 33.3%. Healthcare dominates the top 10 at 33.3% — this is a sector bet, not a diversified mix. Within the top 10, by geography: US 26.5%, Europe 6.9%. 10 of the top 10 holdings also sit in peers' top 10 — high overlap with the category consensus.

Macro

No single macro theme dominates. The portfolio is positioned to move with broad market direction rather than any specific cycle. In a choppy, liquidity-tightening environment that neutrality is defensive; in a trending market it means keeping pace, not leading. One caveat: concentration amplifies macro moves. When funding liquidity tightens, concentrated portfolios tend to chop harder than diversified ones.

Micro

At the stock level there are no outsized single-name risks. The portfolio's behaviour will be driven by sector and market moves, not individual company events.

Summary

Concentrated healthcare exposure at 33.3% of top-10; top-10 concentration 52.5%. Manager runs a disciplined, benchmark-aware portfolio (10/10 top holdings overlap peers). No strong cyclical tilt — stock selection, not macro rotation, will drive returns. Note: near-term liquidity tightening amplifies concentrated-portfolio volatility. High concentration means higher volatility; longer holding periods help smooth cycle swings — best as a satellite, not a single holding.

Independent commentary for information only — not investment advice. Fund figures: provider fact sheet via mpf.hk. Peer comparison: latest available figures on mpf.hk.
Performance

Investment Objective

To provide long term capital growth. Invests on a diversified basis mainly in shares of companies in health care and related industries, covering mainly in pharmaceutical, healthcare equipment & services, food & drug retails, managed care business and biotechnology sectors

Trailing Returns ⓘ

3 Months1 Year3 Years5 Years10 YearsSince LaunchYTD
Cumulative+6.77%+22.65%+24.73%+29.80%+86.88%+251.00%+3.38%
Annualised——+7.65%+5.36%+6.45%+7.12%—

Calendar Year Returns ⓘ

20252024202320222021
Return (%)+18.28%-1.55%+3.95%-6.06%+18.86%

Returns are net of fees. Past performance is not indicative of future returns.

Dollar Cost Averaging Return ⓘ

Cumulative Return

3 MonthsYTD1 Year3 Years5 Years10 YearsSince Launch
Return (%)N/AN/A+10.19%+15.21%+20.07%+43.31%+114.58%

Annualised Return

3 Years5 Years10 YearsSince Launch
Return (% p.a.)+9.41%+7.24%+6.99%+7.78%

Calendar Year Return

20212022202320242025
Return (%)+11.96%+2.30%+5.17%-7.64%+13.79%

Fund Commentary

The world equity markets performed very well in the second quarter, albeit with elevated volatility caused by daily headlines from the Middle East. Investors gradually grew more confident that the war in Iran would wind down quickly and have only a limited impact on global growth, leading to a significant rebound in stocks off their March lows. The markets were further boosted by corporate earnings that came in well above expectations, particularly for US technology companies. Artificial intelligence (AI) continued to be an important theme in the markets, fueling outsized gains for semiconductor and memory stocks. South Korea and Taiwan were notable beneficiaries of this trend, helping the broad-based emerging market (EM) indexes deliver strong returns. The healthcare sector advanced during the period. The healthcare providers and services, life sciences tools and services, and pharmaceuticals sub-sectors advanced, while the healthcare equipment and supplies and biotechnology sub-sectors declined.

Allocation

Portfolio Allocation

Pharmaceuticals
53.4%
Medical Equipment
16.3%
Biotechnology
11.7%
Healthcare Mgt. Services
6.4%
Others
4.4%
Drug Retailers
3.7%
Medical Supplies
2.4%
Cash
1.7%
Top 10 Holdings

Top 10 Holdings

#Security nameHoldings Weight
1Eli Lilly and Co.9.78%
2Johnson & Johnson7.29%
3AbbVie Inc.5.18%
4AstraZeneca PLC5.08%
5Amgen Inc.4.16%
6UnitedHealth Group Inc.3.19%
7Roche Holding Ltd3.17%
8Vertex Pharmaceuticals Inc.2.85%
9Medtronic Plc2.82%
10Stryker Corp.2.73%
Total46.25%
Fees

Fees & Charges

1.91298%
Fund Expense Ratio (FER)

The fund expense ratio shows the total annual cost of running this fund as a percentage of its assets. It is already reflected in the fund price and returns. When comparing similar funds, fees are one of the few factors you can control.

A 1% fee gap can mean a very different retirement pot over 30 years. See the offering document for the full fee schedule.
FER History▼ 0.01pp since 2021 (−0.4%)
2021: 1.92%1.92%20212022: 1.9%1.9%20222023: 1.91%1.91%20232024: 1.92382%1.924%20242025: 1.91298%1.913%2025Now: 1.91298%1.913%Now

FER is a backward-looking figure from the fund's financial year, taken from provider fact sheets and audited annual reports. It may not yet reflect announced fee cuts.

Compare

More funds in this scheme

Manulife MPF Conservative Fund
1-yr return—
FER0.76790%
Manulife MPF Interest Fund
1-yr return—
FER1.76663%
Manulife MPF Age 65 Plus Fund
1-yr return—
FER0.75640%
News

Related news

The materials provided are for information only and do not constitute as an offer. For investment advice, please consult professional advisors. The information contained in this website has been compiled with considerable care to ensure its accuracy at the date of publication. However, no representation or warranty, express or implied, is made to its accuracy or completeness. MPF.HK shall not be responsible for any consequential effect, nor be liable for any direct, consequential, incidental, indirect loss or damage, howsoever caused, arising from the use of, inability to use or reliance upon any information or materials provided on this website, whether or not such loss or damage is caused by MPF.HK. Links to third party sites are provided for your information only. The content and software of these sites have been issued by third parties. As such, MPF.HK cannot be responsible for the accuracy of information contained in these sites, nor be held liable for any loss or damage arising from or related to their use.
funds to compare